黎巴嫩对碳青霉烯类耐药大肠杆菌和肺炎克雷伯菌出现头孢他啶-阿维巴坦耐药性

The International Arabic Journal of Antimicrobial Agents Pub Date : 2021-01-01 DOI:10.3823/858

Ghena M Sobh, Abdul Karim El Karaaoui, M. E. Chaar, G. Araj

{"title":"黎巴嫩对碳青霉烯类耐药大肠杆菌和肺炎克雷伯菌出现头孢他啶-阿维巴坦耐药性","authors":"Ghena M Sobh, Abdul Karim El Karaaoui, M. E. Chaar, G. Araj","doi":"10.3823/858","DOIUrl":null,"url":null,"abstract":"Ceftazidime-avibactam (CZA) has been introduced as a novel drug to essentially combat the rising trends of carbapenem resistant Enterobacteriaceae. In the absence of in vitro data about the activity of this drug against carbapenem resistant (CR) Escherichia coli and Klebsiella pneumoniae in Lebanon, this study was warranted.","PeriodicalId":22518,"journal":{"name":"The International Arabic Journal of Antimicrobial Agents","volume":"38 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Emerging ceftazidime-avibactam resistance against carbapenem resistant Escherichia coli and Klebsiella pneumoniae in Lebanon\",\"authors\":\"Ghena M Sobh, Abdul Karim El Karaaoui, M. E. Chaar, G. Araj\",\"doi\":\"10.3823/858\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ceftazidime-avibactam (CZA) has been introduced as a novel drug to essentially combat the rising trends of carbapenem resistant Enterobacteriaceae. In the absence of in vitro data about the activity of this drug against carbapenem resistant (CR) Escherichia coli and Klebsiella pneumoniae in Lebanon, this study was warranted.\",\"PeriodicalId\":22518,\"journal\":{\"name\":\"The International Arabic Journal of Antimicrobial Agents\",\"volume\":\"38 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The International Arabic Journal of Antimicrobial Agents\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3823/858\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The International Arabic Journal of Antimicrobial Agents","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3823/858","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

头孢他啶-阿维巴坦(CZA)是一种新型药物，主要用于对抗碳青霉烯耐药肠杆菌科的上升趋势。由于缺乏该药物在黎巴嫩抗碳青霉烯耐药(CR)大肠杆菌和肺炎克雷伯菌活性的体外数据，因此本研究是有必要的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Emerging ceftazidime-avibactam resistance against carbapenem resistant Escherichia coli and Klebsiella pneumoniae in Lebanon

Ceftazidime-avibactam (CZA) has been introduced as a novel drug to essentially combat the rising trends of carbapenem resistant Enterobacteriaceae. In the absence of in vitro data about the activity of this drug against carbapenem resistant (CR) Escherichia coli and Klebsiella pneumoniae in Lebanon, this study was warranted.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The International Arabic Journal of Antimicrobial Agents

自引率

0.00%

发文量